Meeting Minutes, Open Session, Drug Utilization Review Board January 19, 2022 10am to 2pm		
Drug Utilization Review Board *Due to COVID-19, this meeting was held virtually.	**DUR Board Members:** Moneeshindra Mittal, MD, Chair (Absent) James Backes, PharmD, Interim Chair (Present) Jennifer Clair, MD (Present) Gregory Burger, PharmD, CPPS, FASHP, EMT (Absent) Michele Reisinger, DNP, APRN, FNP-BC (Present) Kristen Powell, PharmD (Present) Arthur Snow, MD (Present) Daryl Callahan, DO, MSS (Present) **KDHE/DHCF/Contractor Staff:** Annette Grant, RPh. (Present) Victor Nguyen, PharmD (Present) Carol Arace, Administrative Specialist (Present) **DXC Technology Staff/KEPRO Staff** Karen Kluczykowski, RPh (Present) Kathy Kaesewurm, RN, BSN (Present) Harry Vu, PharmD (Present) Christina Faulkner, PharmD, BCPS (Present) **MCO Staff:** Mark DeMary, PharmD, Aetna Better Health of Kansas (Present) Angie Yoo, PharmD, Sunflower State Health Plan (Present) Kelly Flannigan, PharmD, UnitedHealthcare Community Plan (Present)	**Public Attendees**: Ximena Garcia, KDHE; Sunny Bounyalath, UHC; Audrey Rattan, Kenneth Berry, Alkermes; Donna Osterlund, Stacey Repotski, Sanofi; Erin Hohman, Melissa Basil, Kurt Hendrickson, Abbvie; Gina Heinen, Novo Nordisk; Jasmine Inman, Mark Kaiser, Tara McKinley, Otsuka; Jeff Knappen, Spark; Jenny Carrell, J&J; Jill Frandeen, Abbott; Jim Baumann, Pfizer; Keith Gulley, Nishil Patel, Amgen; Lee Ward, BMS; Marc Parker, Sunovion; Porscha Showers, Jennifer Davis, Robert Firnberg, Gilead; Rachel Atkinson, Ricki Roberson, Merck; Sean Jones, Raquel Jordan, Kim Bogard, Takeda; Ryan Reza, NAMI-Kansas. (Only individuals that provided their full name are listed)

TOPIC	DISCUSSION	DECISION
I. Call to Order	Dr. Backes called the meeting to order at 10:06 AM.	
Announcements and Introductions	No announcements or introductions.	
II. Old Business **A. Review and Approval of October 20, 2021 Meeting Minutes**	**Board Discussion:** Dr. Backes asked if there were any amendments/changes to the minutes requested.	Dr. Snow motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.
III. New Business **A. Revised Prior Authorization (PA) Criteria** **1. Adult Rheumatoid Arthritis Agents**	**Background:** This revision includes the addition of Avsola®, Ruxience®, and Truxima® to the list of agents requiring prior authorization. This revision also includes additional criteria for the use of JAK inhibitors. **Public Comment:** Erin Hohman (Abbvie- Rinvoq®) yielded her time back to the Board. **Board Discussion:** The Board asked about indications not covered on the PA criteria, specifically on baricitinib and its Emergency Use Authorization for the treatment of COVID. The State confirmed that EUA indication would be approved and pointed out the blanket statement regarding indications not addressed in the current PA criteria.	Dr. Powell motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
2. Asthma Agents	**Background:** This revision includes an update to the indicated age groups and dosing information for Dupixent® and the addition of Tezspire™ to the list of agents requiring prior authorization. **Public Comment:** Nishil Patel (Amgen- Tezspire™) gave clinical information regarding Tezspire.	Dr. Snow motioned to approve. Dr. Clair seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
	Board Discussion: None.	
3. Atopic Dermatitis Agents	**Background:** This revision includes the addition of Opzelura™ and Adbry™ to the list of agents requiring prior authorization and updates to initial and renewal criteria. **Public Comment:** None. **Board Discussion:** None.	Dr. Reisinger motioned for approval as amended. Dr. Powell seconded the motion. The motion was approved unanimously.
4. Enzyme Replacement Agents	**Background:** This revision includes the migration of Lumizyme® and Nexviazyme® to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** The Board asked about utilization and how common these agents are used. The State replied that utilization data was not readily available but would report on it at the next meeting. (*Towards the end of the meeting, the State provided aggregate data of 176 claims and almost $3 million spent in 2021*). The State also commented that efforts are being made to remove unnecessary PA criteria. The current proposal on the high-dollar drugs represents a reduction in criteria where only diagnosis is required.	Dr. Powell motioned for approval as amended. Dr. Snow seconded the motion. The motion was approved unanimously.
5. Hepatitis C	**Background:** This revision includes updates to the indicated age groups and dosing information and the addition of new formulations of Epclusa® and Mavyret®.	Dr. Snow motioned for approval as amended. Dr. Clair seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
	Public Comment: Erin Hohman (Abbvie- Mavyret®) yielded her time back to the Board. **Board Discussion:** None.	
6. Oncology Agents	**Background:** This revision includes the addition and/or removal of several drugs to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** None.	Dr. Powell motioned for approval as amended. Dr. Clair seconded the motion. The motion was approved unanimously.
7. Oncology - Auxiliary Treatment Agents	**Background:** This revision includes the addition and/or removal of several drugs to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** None.	Dr. Snow motioned to approve. Dr. Callahan seconded the motion. The motion was approved unanimously.
8. Opioid Products Indicated for Pain Management	**Background:** This revision includes the addition of Seglentis® to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** None.	Dr. Snow motioned to approve. Dr. Reisinger seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
B. New Prior Authorization (PA) Criteria **1. Systemic Lupus Erythematosus Agents**	**Background:** This revision consolidates the existing criteria for Benlysta© and new criteria for Saphnelo™. **Public Comment:** None. **Board Discussion:** The Board asked for a reminder on what prompts the State to review or propose PA criteria. The State discussed various reasons, including high-dollar drugs, potential for off-label use, landscape changes, patient safety, cost effectiveness, and utilization/claims data.	Dr. Callahan motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
C. Tentative Agenda Items (MHMAC and PDL Meeting Agenda Items) **1. MHMAC Meeting (January 18, 2022)** **a. ADHD Medications – Safe Use for All Ages**	**Background:** Clarification of PDMP requirements. **Public Comment:** None. **Board Discussion:** The Board asked if the State knew about the availability of a grant for pharmacies to integrate K-TRACs into their EMR systems. The State replied that the State Board of Pharmacy has worked with providers on this and that the grant was limited to the initial connection of K-TRACs. The maintenance costs have been an ongoing expense, depending on the vendor. The Board also asked about federal requirements regarding accountability, tracking, and reporting compliance. The State noted that current federal requirements are limited to notifying providers of the responsibility, but there is currently limited guidance on compliance and reporting. The Board also asked for details on exceptions for long-term care facilities. The State mentioned the following provider bulletins: 21169, 21229, and 21268, for this information.	Dr. Clair motioned to approve. Dr. Callahan seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
b. Antipsychotic Medications – Safe Use for All Ages	**Background:** Revisit the diagnosis requirement. Revisit management of current drugs with new indications. **Public Comment:** Kenneth Berry (Alkermes- Lybalvi®) yielded his time back to the Board. **Board Discussion:** None.	Dr. Powell motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
2. PDL Meeting (January 18, 2022) New PDL Classes **a. Dry Eye Disease**	**Background:** Cequa™, Restasis®, Tyrvaya™, Xiidra™ **Public Comment:** Erin Hohman (Abbvie- Restasis®) yielded her time back to the Board. **Board Discussion:** None.	Dr. Reisinger motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.
b. Immunomodulation Agents- Atopic Dermatitis	**Background:** Adbry™, Dupixent® **Public Comment:** None. **Board Discussion:** None.	Dr. Snow motioned to approve. Dr. Clair seconded the motion. The motion was approved unanimously.
V. Adjourn	The meeting adjourned at 11:52 AM	Dr. Snow motioned to adjourn. Dr. Powell seconded the motion. Motion to adjourn carried.

The next DUR Board meeting is scheduled for April 20, 2022

All approved PA criteria are posted to the KDHE website- https://www.kdhe.ks.gov/206/General-Clinical-Prior-Authorization